Somatic variation and cancer: therapies lost in the mix
Cancer arises as a consequence of mutations in genomes of cancer cells, which over time allow them to proliferate and spread to distant sites. Large-scale sequencing of cancer genomes is revealing an increasing number of potential driver mutations that may allow specific targeting of cancer genes, proteins, and pathways. Comprehensive views of cancer genomes are also revealing enormous heterogeneity of mutation profiles, even among tumours derived from the same organs and having similar pathological characteristics. There are now many examples where mutation profiles observed in tumours have been shown to correlate with clinical features of disease, drug response, and patient outcomes. When ignored, molecular heterogeneity can lead to failures in drug development, as drugs that may have efficacy in subgroups of patients with specific molecular phenotypes may show marginal response when tested in large groups of unselected patients. This article explores issues relevant to the clinical translation of sequence-based mutation profiles in the clinical development of targeted therapies and in the future management of cancer patients.
|ISBN||1432-1203 (Electronic) 0340-6717 (Linking)|
|Authors||Biankin, A. V.; Hudson, T. J.;|
|Responsible Garvan Author|
|Publisher Name||HUMAN GENETICS|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/21643984|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/11079|